Coating compositions for bioactive agents
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Benefits of technology
Problems solved by technology
Method used
Image
Examples
example 1
Release of Rapamycin from Poly(butadiene) and Poly(butyl methacrylate)
[0127] Three solutions were prepared for coating the stents. The solutions included mixtures of poly(1,2-butadiene) (“PBD”, available from Scientific Polymers Products, Inc., Ontario, N.Y., as Catalog # 688; CAS #31567-90-5; 7% cis 1,4; 93% vinyl 1,2; Mw approx. 100 kilodaltons), poly(butyl methacrylate) (“PBMA”, available from Sigma-Aldrich Fine Chemicals as Product No. 18,152-8, having a weight average molecular weight (Mw) of about 337 kilodaltons), and rapamycin (“RAPA”, available from LC Laboratories, Woburn, Mass.) dissolved in THF to form a homogeneous solution. The stents were not given a primer pre-treatment.
[0128] The solutions were prepared to include the following ingredients at the stated weights per milliliter of THF: [0129] 1) 16 mg / ml PBD / 4 mg / ml PBMA / 10 mg / ml RAPA [0130] 2) 10 mg / ml PBD / 10 mg / ml PBMA / 10 mg / ml RAPA [0131] 3) 4 mg / ml PBD / 16 mg / ml PBMA / 10 mg / ml RAPA
[0132] Using the Sample Preparat...
example 2
Release of Rapamycin from Poly(butadiene-co-acrylonitrile) and Poly(butyl methacrylate)
[0135] Three solutions were prepared for coating the stents. The solutions included mixtures of poly(butadiene-co-acrylonitrile) (“PBDA,” available from Scientific Polymer Products, Inc., Catalog #533, contains 41% (wt) acrylonitrile), “PBMA” and “RAPA” (“PBMA” and “RAPA” were obtained and used as described in Example 1) dissolved in THF to form a homogeneous solution. The stents were not given a primer pre-treatment.
[0136] The solutions were prepared to include the following ingredients at the stated weights per milliliter of THF: [0137] 1) 16 mg / ml PBDA / 4 mg / ml PBMA / 0 mg / ml RAPA [0138] 2) 10 mg / ml PBDA / 0 mg / ml PBMA / 0 mg / ml RAPA [0139] 3) 4 mg / ml PBDA / 16 mg / ml PBMA / 10 mg / ml RAPA
[0140] Using the Sample Preparation Procedure, two stents were spray coated using each solution. After solvent removal via ambient evaporation, the drug elution for each coated stent was monitored using the Rapamycin Re...
example 3
Release of Dexamethasone from Poly(butadiene) and Poly(butyl methacrylate)
[0142] Three solutions were prepared for coating the stents. All three solutions included mixtures of poly(1,2-butadiene) “PBD”, poly(butyl methyl acrylate) (“PBMA”), and dexamethasone (“DEXA”) dissolved in THF to form a homogeneous solution. The stents were not given a primer pre-treatment.
[0143] The solutions were prepared to include the following ingredients at the stated weights per milliliter of THF: [0144] 1) 20 mg / ml PBD / 0 mg / ml PBMA / 10 mg / ml DEXA [0145] 2) 10 mg / ml PBD / 10 mg / ml PBMA / 10 mg / ml DEXA [0146] 3) 0 mg / ml PBD / 20 mg / ml PBMA / 10 mg / ml DEXA
[0147] Using the Sample Preparation Procedure, two stents were spray coated using each solution. After solvent removal via ambient evaporation, the drug elution for each coated stent was monitored using the Dexamethasone Release Assay Procedure.
[0148] Results, provided in FIG. 3, demonstrate the ability to control the elution rate of dexamethasone, a pharmac...
PUM
Property | Measurement | Unit |
---|---|---|
Fraction | aaaaa | aaaaa |
Fraction | aaaaa | aaaaa |
Percent by mass | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com